Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Mayne Pharma Group ( (AU:MYX) ) is now available.
Mayne Pharma has announced the registration of its Scheme Booklet with the Australian Securities and Investments Commission, detailing the proposed acquisition by Cosette Pharmaceuticals via a scheme of arrangement. The Independent Expert has deemed the acquisition fair and reasonable, recommending shareholders vote in favor of the scheme. The Scheme Meeting is scheduled for June 18, 2025, where shareholders will decide on the proposal, which is expected to impact Mayne Pharma’s market positioning and shareholder value.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.69 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is a pharmaceutical company listed on the Australian Securities Exchange (ASX: MYX). The company is involved in the development and manufacturing of branded and generic pharmaceutical products, with a focus on providing high-quality and affordable medications to the market.
Average Trading Volume: 826,191
Technical Sentiment Signal: Hold
Current Market Cap: A$551.7M
Learn more about MYX stock on TipRanks’ Stock Analysis page.